Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1ANTI-VON willebrand factor nanobody, caplacizumab
(Cablivi, CABLIVI)
----[1] 64 💬
2ANTI-VON willebrand factor nanobody, INN = caplacizumab
(Cablivi, CABLIVI)
[1] Caplacizumab[1] Caplacizumab (Cablivi, CABLIVI) 💬 [1] VWF 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64 💬
3Cablivi[1] Caplacizumab[1] Caplacizumab (Cablivi, CABLIVI) 💬 [1] VWF 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64 💬
4Cablivi®----[1] 64 💬
5Caplacizumab
(Cablivi, CABLIVI)
[1] Caplacizumab[1] Caplacizumab (Cablivi, CABLIVI) 💬 [1] VWF 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[2] 63, 64 💬